4th International Conference on Medical Imaging with Deep Learning Jul 07, 2021 - Jul 09, 2021 — Virtual Meeting (online)
Medical Image Understanding and Analysis Conference 2021 Jul 12, 2021 - Jul 14, 2021 — Virtual Meeting (online)
Medical Imaging Convention [rescheduled] Sep 15, 2021 - Sep 16, 2021 — National Exhibition Centre, Birmingham, England
2021 SINAPSE ASM Sep 16, 2021 - Sep 17, 2021 — Technology & Innovation Centre, University of Strathclyde, 99 George Street, Glasgow
Total Body PET 2021 conference [rescheduled] Sep 22, 2021 - Sep 24, 2021 — Virtual Meeting (online)


SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.

Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial

Author(s): S. M. Davis, G. A. Donnan, M. W. Parsons, C. Levi, K. S. Butcher, A. Peeters, P. A. Barber, C. Bladin, D. A. De Silva, G. Byrnes, J. B. Chalk, J. N. Fink, T. E. Kimber, D. Schultz, P. J. Hand, J. Frayne, G. Hankey, K. Muir, R. Gerraty, B. M. Tress, P. M. Desmond, Epithet Investigators

Background Whether intravenous tissue plasminogen activator (alteplase) is effective beyond 3 h after onset of acute ischaemic stroke is unclear. We aimed to test whether alteplase given 3-6 h after stroke onset promotes reperfusion and attenuates infarct growth in patients who have a mismatch in perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI). Methods We prospectively and randomly assigned 101 patients to receive alteplase or placebo 3-6 h after onset of ischaemic stroke. PWI and DWI were done before and 3-5 days after therapy, with T2-weighted MRI at around day 90. The primary endpoint was infarct growth between baseline DWI and the day 90 T2 lesion in mismatch patients. Major secondary endpoints were reperfusion, good neurological outcome, and good functional outcome. Patients, caregivers, and investigators were unaware of treatment allocations. Primary analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT00238537. Findings We randomly assigned 52 patients to alteplase and 49 patients to placebo. Mean age was 71.6 years, and median score on the National Institutes of Health stroke scale was 13.85 of 99 (86%) patients had mismatch of PWI and DWI. The geometric mean infarct growth (exponential of the mean log of relative growth) was 1.24 with alteplase and 1.78 with placebo (ratio 0.69, 95% CI 0.38-1.28; Student's t test p=0.239); the median relative infarct growth was 1.18 with alteplase and 1.79 with placebo (ratio 0.66, 0.36-0-92; Wilcoxon's test p=0.054). Reperfusion was more common with alteplase than with placebo and was associated with less infarct growth (p=0.001), better neurological outcome (p<0.0001), and better functional outcome (p=0.010) than was no reperfusion. Interpretation Alteplase was non-significantly associated with lower infarct growth and significantly associated with increased reperfusion in patients who had mismatch. Because reperfusion was associated with improved clinical outcomes, phase III trials beyond 3 h after treatment are warranted.

Full version: Available here

Click the link to go to an external website with the full version of the paper

ISBN: 1474-4422
Publication Year: 2008
Periodical: Lancet Neurology
Periodical Number: 4
Volume: 7
Pages: 299-309
Author Address: